FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Read original at benzingaStocks · News reference
DexCom Selected As First Participant For FDA's TEMPO Digital Health Devices Program
The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health technologies that support chronic disease management while collecting real-world performance data. The initiative is part
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 22, 2026, 9:18 PM
- Checked
- Jul 22, 2026, 9:18 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Argus Research Maintains Buy on DexCom, Raises Price Target to $96
Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.
Read original at benzingaCanaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.
Read original at benzingaCitigroup Maintains Buy on DexCom, Raises Price Target to $88
Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $84 to $88.
Read original at benzinga